HIGHLIGHTS
- who: Tianyu Zeng and colleagues from the Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Guangzhou Road, Nanjing, China have published the paper: A Real-World Multicentre Retrospective Study of Low-Dose Apatinib for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer, in the Journal: Cancers 2022, 4084 of /2022/
- how: This study retrospectively analyzed the clinical data of patients who have metastatic breast cancer and were treated with low dose apatinib and evaluated its clinical efficacy and adverse reactions in the breast cancer field which might provide a new . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.